37 -1 (51) 2023 — Khaidarov K.I., Usmanova D.D. — PROGNOSTIC CRITERIA FOR THE DEVELOPMENT OF HEART FAILURE IN CHILDREN WITH CONGENITAL HEART DEFECTS IN THE EARLY POSTOPERATIVE PERIOD

PROGNOSTIC CRITERIA FOR THE DEVELOPMENT OF HEART FAILURE IN CHILDREN WITH CONGENITAL HEART DEFECTS IN THE EARLY POSTOPERATIVE PERIOD

Khaidarov K.I. Center for the Development of Professional Qualifications of Medical Workers,

Usmanova D.D. Tashkent Pediatric Medical Institute

Resume

This article describes the results of our studies devoted to the study of the features of the biochemical parameters of postoperative vise in congenital heart defects in the early postoperative period. The material of the study was clinical stadiesfor the period october 2022 and january 2023 in departments of pediatric cardiac surgery at the TashPMI clinic and the Eramed multidisciplinary medical center. 58 demi with CHD were examined. It was revealed that the levels of indicators of myocardial damage (Troponin-T, MB-creatinephosphokinase) are associated with manifestations of the hearts failure. The studied laboratory parameters can be regarded as markers of tissue homeostasis disturbance.

Key words: biochemical parameters, congenital heart difects, postoperative period, troponin-T, MB-creatinephosphokinase.

First page

219

Last page

223

For citation: Khaidarov K.I., Usmanova D.D. – PROGNOSTIC CRITERIA FOR THE DEVELOPMENT OF HEART FAILURE IN CHILDREN WITH CONGENITAL HEART DEFECTS IN THE EARLY POSTOPERATIVE PERIOD //New Day in Medicine 1(51)2023 219-223 https://clck.ru/33NWCF

LIST OF REFERENCES:

1. Волошина Н.П., Егоркина О.В., Рязанцев В.В., Черненко М.Е. Креатинкиназемия при боковом амиотрофическом склерозе. Украинский неврологический журнал. 2014;2(31): 31–37 с.
2. Долгов В.В. Клиническая лабораторная диагностика: национальное руководство. Т. 1. М.: ГЭОТАР-Медиа; 2013.
3. Какорин С.В., Былова Н.А. Клинический случай высокого уровня креатинфосфокиназы. Архивъ внутренней медицины. 2015;2(22): 62–64 с.
4. Козлов А.В., Берестовская В.С., Ребякова Е.Н. Гиперкреатинкиназемия как лабораторный маркер. Лабораторная диагностика. 2012;1: 27–31 с.
5. Российское кардиологическое общество. Клинические рекомендации 2020 г. Миокардиты. (Электронный ресурс.) URL: https://scardio.ru/content/Guidelines/2020/Clinic_rekom_Miokardit.pdf.
6. Руженцова Т.А., Милейкова Е.И., Моженкова А.В. и др. Значение повышения MB-креатинкиназы при различной экстракардиальной патологии. Лечащий врач. 2018; – 10. 80–83 с.
7. Острый инфаркт миокарда с подъемом сегмента ST электрокардиограммы. Клинические рекомендации 2020. Российское кардиологическое общество, Ассоциация сердечно-сосудистых хирургов России. Российский кардиологический журнал. 2020;25(11): 4103 с.
8. Ярец Ю.И. Биохимические тесты в практической медицине: практическое пособие для врачей. Часть I. Гомель: ГУ «РНПЦ РМиЭЧ»; 2016.
9. Chang C.C., Liou C.B., Su M.J. et al. Creatine Kinase (CK) — MB-to-Total-CK Ratio: a Laboratory Indicator for Primary Cancer Screening. Asian Pac J Cancer Prev. 2015;16(15): Р. 6599–6603.
10. Moghadam-Kia S., Oddis C.V., Aggarwal R. Approach to asymptomatic creatine kinase elevation. Cleve Clin J Med. 2016;83(1): Р. 37–42.
11. Newman C.B., Preiss D., Tobert J.A. et al. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2019;39(2): Р. 38–81.
12. Thygesen K., Alpert J.S., Jaffe A.S. et al. Executive Group on behalf of the Joint European Society of Cardiology (ESC) / American College of Cardiology (ACC) / American Heart Association (AHA) / World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth Universal Definition of Myocardial Infarction (2018). Glob Heart. 2018;13(4): Р. 305–338.
13. Suleiman H.M., Aliyu I.S., Abubakar S.A. et al. Cardiac Troponin T and creatine kinase MB fraction levels among patients with acute ischemic stroke in Nigeria. Niger J Clin Pract. 2017;20(12): Р. 1618–1621.